$27.44
arrow_drop_up0.36%Key Stats | |
---|---|
Open | $26.00 |
Prev. Close | $25.70 |
EPS | -3.44 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
PE Ratio | - |
LOW | HIGH | |
---|---|---|
Day Range | 25.69 | 27.41 |
52 Week Range | 11.25 | 53.77 |
Ratios | |
---|---|
Revenue | - |
EBITDA Margin % | - |
EPS | -3.44 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Akero Therapeutics CFO sells over $976k in company stock - Investing.com
Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024
Viking (VKTX) Falls 10% Despite Upbeat NASH Study Results
Perrigo (PRGO) to Report Q1 Earnings: Here's What to Expect
Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH